Quick Dispatch:
Your iih and glp 1 GLP-1 Drugs and Ocular Disease: Between Neuroprotection and Risk orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your iih and glp 1 GLP-1 Drugs and Ocular Disease: Between Neuroprotection and Risk ships.
Need Help?
Questions about iih and glp 1 GLP-1 Drugs and Ocular Disease: Between Neuroprotection and Risk, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for iih and glp 1 GLP-1 Drugs and Ocular Disease: Between Neuroprotection and Risk in your area.
Beyond weight loss: a case study and narrative review of the potential role of glucagon-like peptide-1 receptor agonists for the treatment of idiopathic intracranial hypertension - Paulo
20.49
GLP-1 programs the neurovascular landscape: Cell Metabolism
28.56
A retrospective cohort study assessed outcomes among patients with idiopathic intracranial hypertension who received glucagon-like peptide-1 receptor agonists
28.93
University of Birmingham Metabolic Concepts in Idiopathic Intracranial Hypertension and Their Potential for Therapeutic Interven
21.28
GLP-1 receptor agonists may improve outcomes in idiopathic intracranial hypertension
22.54
Journal club: GLP-1 receptor agonists in idiopathic intracranial hypertension
29.70
Perturbed metabolic pathways in IIH which may contribute toward
27.65
